Has anyone given thought to the collaborative R&D that was undertaken a couple of years ago with Carina Biotech? As we know, the IP derived from that collab along with our ongoing collab with Peter Mac bestowed PTX with CellPryme. The reason I ask is because Carina's Car-T clinical trial in colorectal cancer is now recruiting-
PTX was granted the full rights to the IP and what did Carina gain out of the arrangement, I wonder!? Bec is the stem cell queen plus at the time we had the targeted therapies of PTX-100 and 200 in clinical trials. The technology behind PTX-200 forms the backbone (if you like) of CellPryme. So, I wonder whether our collab imparted technology from our resultant cell therapy (ie. they are using CellPryme manufactured cells in their trial) or whether our collab contributed to the R&D of their colorectal program directly at the time. The collab, of course, was flagged as confidential from the outset... and, certainly, still is.
Btw, PTX-100 was initally trialed with a basket of different solid tumours, inc. colon and/or gastro-intestinal tumours.
PTX Price at posting:
5.5¢ Sentiment: Buy Disclosure: Held
